Deepa Sampath, Ph.D.
Department of Hematopoietic Biology & Malignancy, Division of Cancer Medicine
About Dr. Deepa Sampath
Patient Load: Neuroradiology: About 20-40 diagnostic cases per day, with average 3 myelograms, 2 spinal interventions and 1 angiogram/spinal interventional procedure per week. Regular scheduled and unscheduled consultations are performed with referring
Read More
Present Title & Affiliation
Primary Appointment
Professor (Joint Appointment), Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Professor, Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor (Joint Appointment), Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
Professor, Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, Texas
Research Interests
Epigenetic mechanisms play a critical role in the pathogenesis of leukemias and are rational targets for therapeutic modulation. Chronic lymphocytic leukemia and other indolent leukemias accumulate due to a persistence of cells with enhanced survival capacity. Resistance to apoptosis in these tumors is mediated by the selective repression of proapoptotic signaling pathways as well as the overexpression of survival promoting genes. Using CHIP assays, microarrays, gene expression assays and immunoblotting in primary tumor cells, research in my lab is focused on: 1) understanding the patterns of epigenetic silencing via methylation of DNA and histones, histone deacetylation and recruitment of polycomb repressor complexes to the gene promoters of microRNA and other genes in indolent leukemias, 2) Pharmacological re-expression with an aim to elucidating the physiological role of microRNA and other genes in regulating the apoptotic signaling in indolent leukemias. Our research projects provide the opportunity to study the epigenetic mechanisms that may contribute to the pathogenesis of indolent and aggressive leukemia and to translate these findings into novel therapeutic strategies against these diseases.
Education & Training
Degree-Granting Education
| 1995 | University of Texas Medical Branch, Galveston, Texas, US, Human Biological Chemistry and Genetics, Ph.D |
| 1988 | University of Madras, Chennai, IN, Medical Genetics, M.S |
| 1986 | University of Madras, Chennai, IN, Zoology, BS |
Postgraduate Training
| 1998-2004 | Research Associate, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 1995-1998 | Postdoctoral Fellowship, The University of Texas MD Anderson Cancer Center, Houston, Texas |
Experience & Service
Faculty Academic Appointments
Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - 2024
Associate Professor, Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2024
Associate Professor, Department of Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, OH, 2019 - 2020
Assistant Professor, Department of Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, OH, 2013 - 2019
Adjunct Assistant Professor, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2015
Assistant Professor, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2012
Instructor, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2004 - 2007
Other Professional Positions
Member, TL1 Fellowship Committee, Houston, TX, 2022 - Present
Committee Member, GSBS Membership Committee, Houston, TX, 2021 - Present
Member, TL1 Advisory Board, Houston, TX, 2021 - Present
Consultant and Board Member, Newave, San Francisco, 2020 - Present
Basic Science Leader, Section of CLL and Hairy Cell Leukemia, Columbus, OH, 2019
Committee Member, Division of Hematology Division Supported Research Program (DSRP) Committee, OSU, Columbus, OH, 2018
Committee Member, Basic Science Graduate Program, OSU, Columbus, OH, 2016
Committee Member, Molecular, Cellular and Developmental Biology Graduate Program, OSU, Columbus, OH, 2016
Committee Member, Leukemia Research Program, OSU, Columbus, OH, 2016
Basic Science Leader, Discovery Post-baccalaureate Research Education Program (PREP) OSU, Columbus, OH, 2016
Committee Member, Department of Internal Medicine Resident Interview Committee, OSU, Columbus, OH, 2014
Committee Member, Division of Hematology Faculty Interview Committee, OSU, Columbus, OH, 2014
Associate Faculty Member, Graduate School of Biomedical Sciences, Houston, TX, 2007 - 2012
Extramural Institutional Committee Activities
Member, Promotion and Tenure Commitee-Research, The University of Texas MD Anderson Cancer Center, 2024 - Present
Faculty Senate Executive Committee, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2023 - 2025
Member, Faculty Senate Representative-HBM, The University of Texas MD Anderson Cancer Center, 2021 - 2023
Evaluator, Ad Hoc Research Integrity Office Faculty, The University of Texas MD Anderson Cancer Center, 2021 - Present
Editorial Activities
Editoral Board Member and reviewer, HemaSphere, 2025 - Present
Reviewer, Clinical cancer research : an official journal of the American Association for Cancer Research, 2011 - Present
Editoral Board Member and reviewer, Hematology Oncology, 2011 - Present
Editoral Board Member and reviewer, Blood, 2009 - Present
Editoral Board Member, Leukemia and Lymphoma, 2008 - Present
Honors & Awards
| 2024 - Present | MD Anderson’s Celebration of Faculty Excellence - Education and Mentorship Advancement, MD Anderson |
| 2019 | Graduate Student Mentor Award, The Ohio State University College of Medicine |
| 2015 | Translational Cancer Research Award, International Conference on Translational Cancer Research |
| 2012 | Research Scholar Award, American Cancer Society |
| 2011 | Inaugural Institutional Grand Rounds, MD Anderson Cancer Center |
| 2001 | AFLAC Scholar-in-Training Award, American Association for Cancer Research |
| 1997 | Glaxo-Wellcome Oncology Clinical Research Scholar Award, American Association for Cancer Research |
| 1990 | Beale Scholarship, University of Texas Medical Branch |
| 1984 | Scholarship for Academic Excellence, Ethiraj |
Professional Memberships
Selected Presentations & Talks
Regional Presentations
- 2011. Epigenetic regulation of microRNA in leukemia. Conference. MD Anderson Cancer Center, US.
National Presentations
- 2009. Chromatin modulation in CLL. Invited. US European Alliance. Berlin, US.
International Presentations
- 2022. Therapies for Venetoclax Refractory CLL. Invited. Chronic Lymphocytic Leukemia (CLL) Research. Winnipeg, CA.
- 2015. Overcoming Resistance in Leukemia. Invited. University Grants Commission and The US Consulate General. Coimbatore, IN.
- 2010. Non coding RNA in CLL. Invited. US European Alliance. Torrent, ES.
- 2008. Specific activation of microRNA 106b targets the ubiquitin ligase ITCH to enable the p73 apoptotic response in chronic lymphocytic leukemia. Conference. PLENARY PRESENTATION at the EORTC-NCIMolecular Targets and Cancer Therapeutics. Geneva, CH.
- 2008. Chromatin modulation to target CLL. Invited. US European Alliance. Lake Orta, IT.
- 2007. Histone deacetylase inhibitors activate p73 to target chronic lymphocytic leukemia. Conference. International Workshop on CLL. London, GB.
Formal Peers
- 2018. Mechanism based drug development for CLL in the post-ibrutinib era. Invited. Houston, TX, US.
Grant & Contract Support
| Date: | 2023 - 2027 |
| Title: | Improving BTK directed therapy in CLL |
| Funding Source: | Ohio State University |
| Role: | Co-I |
| Date: | 2023 - 2026 |
| Title: | Inhibition of PKCβ as a strategy for BTK inhibitor refractory CLL |
| Funding Source: | Leukemia & Lymphoma Society |
| Role: | Co-I |
| Date: | 2022 - 2025 |
| Title: | Moon Shot Priority Project: CLL Transformation |
| Funding Source: | UTMDACC Moon Shot |
| Role: | PI |
| Date: | 2022 - 2025 |
| Title: | Moon Shot Priority Project: T/NK |
| Funding Source: | NIH |
| Role: | PI |
| Date: | 2022 - 2027 |
| Title: | Overcoming BCL2 resistance in CLL |
| Funding Source: | OSU |
| Role: | Co-PI |
| Date: | 2021 - 2026 |
| Title: | OSU Leukemia SPORE |
| Funding Source: | OSU |
| Role: | Co-I |
| Date: | 2021 - 2023 |
| Title: | New therapies for high risk CLL |
| Funding Source: | CLL Global Research Foundation |
| Role: | PI |
| Date: | 2019 - 2025 |
| Title: | A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma |
| Funding Source: | R01CA235673 |
| Role: | PI |
| ID: | R01CA235673 |
| Date: | 2019 - 2023 |
| Title: | Characterization of Onalespib, A novel long acting Hsp90 inhibitor, as a chemo and radiosensitizer in Adults with Newly Diagnosed Glioblastoma |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | R01CA235673-01 |
| Date: | 2018 - 2024 |
| Title: | Targeting NAMPT in Acute Myeloid Leukemia |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5R01CA223165-03 |
| Date: | 2017 - 2020 |
| Title: | Therapies of genomic high risk CLL |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | PI |
| Date: | 2015 - 2020 |
| Title: | Pathogenesis and treatment of Richter's transformation |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Co-I |
| Date: | 2015 - 2015 |
| Title: | Epigenetic modulation of microRNA to target BTK for therapy of genomic high risk CLL |
| Funding Source: | Leukemia Research Program |
| Role: | PI |
| Date: | 2015 - 2020 |
| Title: | Targeted Therapies for Richter's Transformation |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA214046-01 |
| Date: | 2012 - 2016 |
| Title: | Epigenetic modulation of non-coding RNA as a therapeutic target in CLL |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2012 - 2015 |
| Title: | Novel Pharmacologic Agent in CLL |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1-P01-CA81534 |
| Date: | 2012 - 2017 |
| Title: | The microRNA epigenome in CLL |
| Funding Source: | American Cancer Society (ACS) |
| Role: | PI |
| ID: | RSG-12-072-01 |
| Date: | 2012 - 2018 |
| Title: | Mechanism based combinations in CLL |
| Funding Source: | US European Alliance |
| Role: | PI |
| Date: | 2012 - 2015 |
| Title: | Biochemical basis of therapy in AML |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 R01 CA 28596 |
| Date: | 2010 - 2012 |
| Title: | Epigenetic modulation of microRNA in CLL: Implications for therapeutic targeting |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2009 - 2010 |
| Title: | Targeting epigenetically silenced microRNA pathways for the therapy of chronic lymphocytic leukemia |
| Funding Source: | Ladies Leukemia League |
| Role: | PI |
| Date: | 2008 - 2012 |
| Title: | Chromatin Modulation as a Therapeutic Strategy for CLL |
| Funding Source: | US-European Alliance for Chronic Lymphocytic leukemia |
| Role: | PI |
| Date: | 2007 - 2008 |
| Title: | MEMGEN ISF35 As an adjunct therapy in combination with chemo and biological therapies for the treatment of patients with B-cell malignancies |
| Funding Source: | Memgen |
| Role: | PI |
| Date: | 2006 - 2008 |
| Title: | Transcriptional activation to target CLL |
| Funding Source: | CLL Global Research Foundation |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Swaminathan M, Ferrajoli A, Thompson PA, Burger J, Borthakur G, Takahashi K, Estrov Z, Bharathi V, Bataller A, Kadia TM, Pemmaraju N, Daver N, Jabbour E, Bose P, Kanagal-Shamanna R, Patel KP, Wang SA, Garg N, Hwang H, Wang X, Qiao W, Xu X, Cruz N, Ayala A, Pierce S, Plunkett W, Sampath D, Kantarjian HM, Keating MJ, Gandhi V, Wierda WG, Jain N. Ibrutinib with venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia: A phase II study. Blood Cancer Discov, 2026. e-Pub 2026. PMID: 41678768.
- Sanchez JR 2nd, Liu C, Pawar V, Huang Y, Diaz-Rohena D, Singh J, Koppikar P, Lai TH, St John L, Puduvalli V, Molldrem J, Thandapani P, Jain N, Lapalombella R, Sampath D. NAMPT inhibition uncovers therapeutic vulnerabilities to venetoclax and chemotherapy in acute myelogenous leukemia. Leuk Lymphoma 67(1):97-107, 2026. e-Pub 2026. PMID: 41401031.
- Gordon BK, Muhowski EM, Singh J, Ravikrishnan J, Peris-Cuesta A, Diaz Rohena D, Sanchez JR, Thangavadivel S, Benrashid S, He A, Marr AR, Mitchell AD, Urrutia JM, Misra S, Lai TH, Yu L, Walker BR, Perry E, Shukla SA, Grieselhuber NR, Rogers KA, Lapalombella R, Blachly JS, Kittai AS, Bhat SA, Jain N, Wierda WG, Byrd JC, Niesman M, Zhang K, Sampath D, Woyach JA. PKCbeta inhibitor MS-553 displays preclinical efficacy in both treatment-naive and BTK inhibitor-resistant Chronic Lymphocytic Leukemia. Blood Cancer Discov, 2025. e-Pub 2025. PMID: 41190953.
- Arani N, Rausch CR, Geppner A, Borthakur G, Jain N, Ferrajoli A, Jabbour E, Sampath D, Hosing C, Vega F, Kantarjian HM, Kadia TM. Cladribine and venetoclax combined with alemtuzumab in patients with relapsed/refractory T-cell prolymphocytic leukemia. Leuk Lymphoma:1-5, 2025. e-Pub 2025. PMID: 41124080.
- Black GS, Huang X, Qiao Y, Moos P, Sampath D, Stephens DM, Woyach JA, Marth GT. Long-read single-cell RNA sequencing enables the study of cancer subclone-specific genotypes and phenotypes in chronic lymphocytic leukemia. Genome Res 35(4):686-697, 2025. e-Pub 2025. PMID: 39965935.
- Ravikrishnan J, Diaz-Rohena DY, Muhowski E, Mo X, Lai TH, Misra S, Williams CD, Sanchez J, Mitchell A, Satpati S, Perry E, Kaufman T, Liu C, Lozanski A, Lozanski G, Rogers K, Kittai AS, Bhat SA, Collins MC, Davids MS, Jain N, Wierda WG, Lapalombella R, Byrd JC, Tan F, Chen Y, Chen Y, Shen Y, Anthony SP, Woyach JA, Sampath D. LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia. Haematologica 110(1):78-91, 2025. e-Pub 2025. PMID: 39113656.
- Sampath D. Role of the Crosstalk B:Neoplastic T Follicular Helper Cells in the Pathobiology of Nodal T Follicular Helper Cell Lymphomas. Elsevier 104(11), 2024. e-Pub 2024. PMID: 39389311.
- Sampath D. LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclax-resistant chronic lymphocytic leukemia. haematologica, 2024.
- Black GS, Huang X, Qiao Y, Moos P, Sampath D, Stephens DM, Woyach JA, Marth GT. Long-read single-cell RNA sequencing enables the study of cancer subclone-specific genotype and phenotype in chronic lymphocytic leukemia. bioRxiv, 2024. e-Pub 2024. PMID: 38559060.
- Lai TH, Ozer HG, Gasparini P, Nigita G, Distefano R, Yu L, Ravikrishnan J, Yilmaz S, Gallegos J, Shukla S, Puduvalli V, Woyach J, Lapalombella R, Blachly J, Byrd JC, Sampath D. HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia. Blood Adv 7(12):2897-2911, 2023. e-Pub 2023. PMID: 36287107.
- Sher S, Whipp E, Walker J, Zhang P, Beaver L, Williams K, Orwick S, Ravikrishnan J, Walker B, Perry E, Gregory C, Purcell M, Pan A, Yan P, Alinari L, Johnson AJ, Frigault MM, Greer JM, Hamdy A, Izumi R, Mo X, Sampath D, Woyach J, Blachly J, Byrd JC, Lapalombella R. VIP152 is a Selective CDK9 Inhibitor with Pre-Clinical In Vitro and In Vivo Efficacy in Chronic Lymphocytic Leukemia. Leukemia 37(2):326-338, 2023. e-Pub 2023. PMID: 36376377.
- Muhowski EM, Ravikrishnan J, Gordon B, Yu L, Misra S, Walker B, Eathiraj S, Sampath D, Rogers KA, Byrd JC, Woyach JA. Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia. J Hematol Oncol 15(1):166, 2022. e-Pub 2022. PMID: 36380319.
- Yano M, Sharpe C, Lance JR, Ravikrishnan J, Zapolnik K, Mo X, Woyach JA, Sampath D, Kittai AS, Vasu S, Bhat S, Rogers KA, Lee DA, Muthusamy N, Byrd JC. Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy. Blood Adv 6(20):5641-5654, 2022. e-Pub 2022. PMID: 35486482.
- Zhang P, Brinton LT, Gharghabi M, Sher S, Williams K, Cannon M, Walker JS, Canfield D, Beaver L, Cempre CB, Phillips H, Chen X, Yan P, Lehman A, Scherle P, Wang M, Vaddi K, Baiocchi R, Wang R, Sampath D, Alinari L, Blachly JS, Lapalombella R. Targeting OXPHOS de novo purine synthesis as the nexus of FLT3 inhibitor-mediated synergistic antileukemic actions. Sci Adv 8(37):eabp9005, 2022. e-Pub 2022. PMID: 36112677.
- Cherng HJ, Khwaja R, Kanagal-Shamanna R, Tang G, Burger J, Thompson P, Ferrajoli A, Estrov Z, Sasaki K, Sampath D, Wang X, Kantarjian H, Keating M, Wierda WG, Jain N. TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. Am J Hematol 97(8):1005-1012, 2022. e-Pub 2022. PMID: 35567779.
- Xu J, Wu PJ, Lai TH, Sharma P, Canella A, Welker AM, Beattie CE, Elder JB, Easley M, Lonser R, Jacob NK, Pietrzak M, Timmers CM, Lang F, Sampath D, Puduvalli VK. Disruption of DNA Repair and Survival Pathways through Heat Shock Protein inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation therapy. Clin Cancer Res 28(9):1979-1990, 2022. e-Pub 2022. PMID: 35140124.
- Sharma P, Xu J, Williams K, Easley M, Elder JB, Lonser R, Lang FF, Lapalombella R, Sampath D, Puduvalli VK. Inhibition of nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of the nicotinamide adenine dinucleotide salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress. Neuro Oncol 24(2):229-244, 2022. e-Pub 2022. PMID: 34260721.
- Mitchell S, Zhang P, Cannon M, Beaver L, Lehman A, Harrington B, Sampath D, Byrd JC, Lapalombella R. Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation. J Hematol Oncol 14(1):101, 2021. e-Pub 2021. PMID: 34187548.
- Zhang P, Brinton LT, Williams K, Sher S, Orwick S, Tzung-Huei L, Mims AS, Coss CC, Kulp SK, Youssef Y, Chan WK, Mitchell S, Mustonen A, Cannon M, Phillips H, Lehman AM, Kauffman T, Beaver L, Canfield D, Grieselhuber NR, Alinari L, Sampath D, Yan P, Byrd JC, Blachly JS, Lapalombella R. Targeting DNA damage repair functions of two histone deacetylases, HDAC8 and SIRT6, sensitizes acute myeloid leukemia to NAMPT inhibition. Clin Cancer Res 27(8):2352-2366, 2021. e-Pub 2021. PMID: 33542077.
- Mims AS, Kohlschmidt J, Eisfeld AK, Mr?zek K, Blachly JS, Orwick S, Papaioannou D, Nicolet D, Sampath D, Stone RM, Powell BL, Kolitz JE, Byrd JC, Bloomfield CD. Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations. Leukemia 35(4):1188-1192, 2021. e-Pub 2021. PMID: 32759975.
- Chen TL, Harrington B, Truxall J, Wasmuth R, Prouty A, Sloan S, Lehman AM, Sampath D, Orlemans E, Baiocchi RA, Alinari L, Byrd JC, Woyach JA, Hertlein E. Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL. J Hematol Oncol 14(1):36, 2021. e-Pub 2021. PMID: 33627156.
- Asiaee A, Abrams ZB, Nakayiza S, Sampath D, Coombes KR. Explaining Gene Expression Using Twenty-One MicroRNAs. J Comput Biol 27(7):1157-1170, 2020. e-Pub 2020. PMID: 31794247.
- Lucas F, Larkin K, Gregory CT, Orwick S, Doong TJ, Lozanski A, Lozanski G, Misra S, Ngankeu A, Ozer HG, Sampath D, Thangavadivel S, Yilmaz SA, Rogers KA, Byrd JC, Woyach JA, Blachly JS. Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations. Blood 135(24):2192-2195, 2020. e-Pub 2020. PMID: 32232486.
- Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Koller PB, Jacamo R, Burks JK, DiNardo C, Daver N, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Leverson JD, Sampath D, Konopleva M. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica 105(3):697-707, 2020. e-Pub 2020. PMID: 31123034.
- Lucas F, Rogers KA, Harrington BK, Pan A, Yu L, Breitbach J, Bundschuh R, Goettl VM, Hing ZA, Kanga P, Mantel R, Sampath D, Smith LL, Wasmuth R, White DK, Yan P, Byrd JC, Lapalombella R, Woyach JA. Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma. Clin Cancer Res 25(20):6260-6273, 2019. e-Pub 2019. PMID: 31296529.
- Lai TH, Mitchell S, Wu PJ, Orwick S, Liu C, Ravikrishnan J, Woyach J, Mims A, Plunkett W, Puduvalli VK, Byrd JC, Lapalombella R, Sampath D. HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics. Leuk Lymphoma 60(9):2308-2311, 2019. e-Pub 2019. PMID: 30773117.
- Iavarone C, Zervantonakis IK, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis UA, Hallberg D, Velculescu VE, Leverson JD, Sampath D, Mills GB, Brugge JS. Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. Mol Cancer Ther 18(3):642-655, 2019. e-Pub 2019. PMID: 30679390.
- Mitchell SR, Larkin K, Grieselhuber NR, Lai TH, Cannon M, Orwick S, Sharma P, Asemelash Y, Zhang P, Goettl VM, Beaver L, Mims A, Puduvalli VK, Blachly JS, Lehman A, Harrington B, Henderson S, Breitbach JT, Williams KE, Dong S, Baloglu E, Senapedis W, Kirschner K, Sampath D, Lapalombella R, Byrd JC. Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia. Blood Adv 3(3):242-255, 2019. e-Pub 2019. PMID: 30692102.
- Calore F, Londhe P, Fadda P, Nigita G, Casadei L, Marceca GP, Fassan M, Lovat F, Gasparini P, Rizzotto L, Zanesi N, Jackson D, Mehta S, Nana-Sinkam P, Sampath D, Pollock RE, Guttridge DC, Croce CM. The TLR7/8/9 Antagonist IMO-8503 Inhibits Cancer-Induced Cachexia. Cancer Res 78(23):6680-6690, 2018. e-Pub 2018. PMID: 30209066.
- Reiff SD, Mantel R, Smith LL, Greene JT, Muhowski EM, Fabian CA, Goettl VM, Tran M, Harrington BK, Rogers KA, Awan FT, Maddocks K, Andritsos L, Lehman AM, Sampath D, Lapalombella R, Eathiraj S, Abbadessa G, Schwartz B, Johnson AJ, Byrd JC, Woyach JA. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. Cancer Discov 8(10):1300-1315, 2018. e-Pub 2018. PMID: 30093506.
- Rizzotto L, Lai TH, Bottoni A, Woyach JA, Lapalombella R, Bloomfield CD, Byrd JC, Sampath D. Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia. Leuk Lymphoma 59(6):1461-1465, 2018. e-Pub 2018. PMID: 28918688.
- Ozer HG, El-Gamal D, Powell B, Hing ZA, Blachly JS, Harrington B, Mitchell S, Grieselhuber NR, Williams K, Lai TH, Alinari L, Baiocchi RA, Brinton L, Baskin E, Cannon M, Beaver L, Goettl VM, Lucas DM, Woyach JA, Sampath D, Lehman AM, Yu L, Zhang J, Ma Y, Zhang Y, Spevak W, Shi S, Severson P, Shellooe R, Carias H, Tsang G, Dong K, Ewing T, Marimuthu A, Tantoy C, Walters J, Sanftner L, Rezaei H, Nespi M, Matusow B, Habets G, Ibrahim P, Zhang C, Mathé EA, Bollag G, Byrd JC, Lapalombella R. BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor. Cancer Discov 8(4):458-477, 2018. e-Pub 2018. PMID: 29386193.
- Canella A, Welker AM, Yoo JY, Xu J, Abas FS, Kesanakurti D, Nagarajan P, Beattie CE, Sulman EP, Liu J, Gumin J, Lang FF, Gurcan MN, Kaur B, Sampath D, Puduvalli VK. Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas. Clin Cancer Res 23(20):6215-6226, 2017. e-Pub 2017. PMID: 28679777.
- Kesanakurti D, Maddirela D, Banasavadi-Siddegowda YK, Lai TH, Qamri Z, Jacob NK, Sampath D, Mohanam S, Kaur B, Puduvalli VK. A novel interaction of PAK4 with PPARgamma to regulate Nox1 and radiation-induced epithelial-to-mesenchymal transition in glioma. Oncogene 36(37):5309-5320, 2017. e-Pub 2017. PMID: 28534509.
- Miller CR, Ruppert AS, Fobare S, Chen TL, Liu C, Lehman A, Blachly JS, Zhang X, Lucas DM, Grever MR, Tallman MS, Flinn IW, Rassenti LZ, Kipps TJ, Sampath D, Coombes KR, Hertlein EK. The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget 8(16):25942-25954, 2017. e-Pub 2017. PMID: 28412730.
- Bottoni A, Rizzotto L, Lai TH, Liu C, Smith LL, Mantel R, Reiff S, El-Gamal D, Larkin K, Johnson AJ, Lapalombella R, Lehman A, Plunkett W, Byrd JC, Blachly JS, Woyach JA, Sampath D. Targeting BTK through microRNA in chronic lymphocytic leukemia. Blood 128(26):3101-3112, 2016. e-Pub 2016. PMID: 27756747.
- Ranganathan P, Kashyap T, Yu X, Meng X, Lai TH, McNeil B, Bhatnagar B, Shacham S, Kauffman M, Dorrance AM, Blum W, Sampath D, Landesman Y, Garzon R. XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus. Clin Cancer Res 22(24):6142-6152, 2016. e-Pub 2016. PMID: 27358488.
- Lai TH, Ewald B, Zecevic A, Liu C, Sulda M, Papaioannou D, Garzon R, Blachly JS, Plunkett W, Sampath D. HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia. Clin Cancer Res 22(14):3537-49, 2016. e-Pub 2016. PMID: 26858310.
- Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, List AF, Sebti S, Kantarjian HM, Ravandi F, Lancet JE. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leuk Res 37(11):1461-7, 2013. e-Pub 2013. PMID: 23993427.
- Gopisetty G, Xu J, Sampath D, Colman H, Puduvalli VK. Epigenetic regulation of CD133/PROM1 expression in glioma stem cells by Sp1/myc and promoter methylation. Oncogene 32(26):3119-29, 2013. e-Pub 2013. PMID: 22945648.
- Sampath D, Liu C, Vasan K, Sulda M, Puduvalli VK, Wierda WG, Keating MJ. Histone deacetylases mediate the silencing of miR-15a and miR-16 and miR-29b in chronic lymphocytic leukemia. Blood 119(5):1162-72, 2012. e-Pub 2012. PMID: 22096249.
- Xu J, Sampath D, Lang FF, Prabhu S, Rao G, Fuller GN, Liu Y, Puduvalli VK. Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures. J Neurooncol 105(2):241-51, 2011. e-Pub 2011. PMID: 21598070.
- Zecevic A, Sampath D, Ewald B, Chen R, Wierda W, Plunkett W. Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease. Clin Cancer Res 17(14):4731-41, 2011. e-Pub 2011. PMID: 21632856.
- Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE, Valeri N, Calore F, Sampath D, Fanini F, Vannini I, Musuraca G, Dell'Aquila M, Alder H, Davuluri RV, Rassenti LZ, Negrini M, Nakamura T, Amadori D, Kay NE, Rai KR, Keating MJ, Kipps TJ, Calin GA, Croce CM. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 305(1):59-67, 2011. e-Pub 2011. PMID: 21205967.
- Liu Y, Lang F, Xie X, Prabhu S, Xu J, Sampath D, Aldape K, Fuller G, Puduvalli VK. Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts. Cell Death Dis 2(N/A):e121, 2011. e-Pub 2011. PMID: 21368892.
- Wierda WG, Castro JE, Aguillon R, Sampath D, Jalayer A, McMannis J, Prussak CE, Keating M, Kipps TJ. A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia 24(11):1893-900, 2010. e-Pub 2010. PMID: 20882050.
- Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D, Fabbri M, Lerner S, Barron LL, Rassenti LZ, Jiang L, Xiao L, Hu J, Secchiero P, Zauli G, Volinia S, Negrini M, Wierda W, Kipps TJ, Plunkett W, Coombes KR, Abruzzo LV, Keating MJ, Calin GA. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 116(6):945-52, 2010. e-Pub 2010. PMID: 20393129.
- Sampath D, Calin GA, Puduvalli VK, Gopisetty G, Taccioli C, Liu CG, Ewald B, Liu C, Keating MJ, Plunkett W. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood 113(16):3744-53, 2009. e-Pub 2009. PMID: 19096009.
- Ewald B, Sampath D, Plunkett W. ATM and the Mre11-Rad50-Nbs1 complex respondto nucleoside analogue-induces stalled replications forks and contribute to drug resistance. Cancer Res 68(19):7947-55, 2008. e-Pub 2008. PMID: 18829552.
- Ewald B, Sampath D, Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther 4(4):1239-1248, 2007. e-Pub 2007. PMID: 17406032.
- Moufarij MA, Sampath D, Keating MJ, Plunkett W. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood 108(13):4187-4193, 2006. e-Pub 2006. PMID: 16954499.
- Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, Gandhi V, Plunkett W. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 107(6):2517-2524, 2006. e-Pub 2006. PMID: 16293603.
- Puduvalli VK, Sampath D, Bruner JM, Nangia J, Xu R, Kyritsis AP. TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis 10(1):233-243, 2005. e-Pub 2005. PMID: 15711939.
- Sampath D, Shi Z, Plunkett W. Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine. Mol Pharmacol 62(3):680-688, 2002. e-Pub 2002. PMID: 12181445.
- Shi Z, Azuma A, Sampath D, Li YX, Huang P, Plunkett W. S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine (UCN-01). Cancer Research 61:1065-1072, 2001. e-Pub 2001. PMID: 11221834.
- Sampath D, Plunkett W. The role of c-jun kinase in the apoptotic response to nucleoside analogue-induced DNA damage. Cancer Research 60:6408-6415, 2000. e-Pub 2000. PMID: 11103806.
- Pan Z, Sampath D, Jackson G, Werrbach-Perez K, Perez-Polo R. NGF and oxidative stress in the nervous system. Adv in Exptl Med Biol 429:173-193, 1997. e-Pub 1997.
- Sampath D, Perez-Polo JR. Regulation of antioxidant enzyme expression by NGF. Neurochem Research 22:351-362, 1997. e-Pub 1997. PMID: 9130244.
- Sampath D, Holets V, Perez-Polo JR. Effect of a spinal cord photolesion injury on catalase. Int J Dev Neurosci 13:645-654, 1995. e-Pub 1995. PMID: 8553900.
- Sampath D, Jackson GR, Werrbach-Perez K, Perez-Polo JR. Effects of nerve growth factor on glutathione peroxidase and catalase in PC12 cells. J Neurochem 62(6):2476-2479, 1994. e-Pub 1994. PMID: 8189251.
- Jackson GR, Sampath D, Werrbach-Perez K, Perez-Polo JR. Effects of nerve growth factor on catalase and glutathione peroxidase in a hydrogen peroxide resistant pheochromocytoma subclone. Brain Research 634:69-76, 1994. e-Pub 1994. PMID: 8156393.
Invited Articles
- Ewald B, Sampath D, Plunkett W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 27(50):6522-37, 2008. e-Pub 2008. PMID: 18955977.
- Tili E, Michaille JJ, Gandhi V, Plunkett W, Sampath D, Calin GA. miRNAs and their potential for use against cancer and other diseases. Future Oncol 3(5):521-37, 2007. e-Pub 2007. PMID: 17927518.
- Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 22(56):9063-9074, 2003. e-Pub 2003. PMID: 14663485.
- Sampath D, Plunkett W. Design of new anti-cancer therapies targeting cell cycle checkpoint pathways. Curr Opin Oncol 13(6):484-490, 2001. e-Pub 2001. PMID: 11673689.
Review Articles
- Sampath D, Plunkett W. The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance. Curr Oncol Rep 9(5):361-7, 2007. e-Pub 2007. PMID: 17706164.
- Jackson GR, Werrbach-Perez K, Pan Z, Sampath D, Perez-Polo JR. Neurotrophin regulation of energy homeostasis in the central nervous system. Dev Neurosci 16:285-290, 1994. e-Pub 1994. PMID: 7768207.
Editorials
- Sampath D. Shielding p53 from destruction. Blood 131(25):2740-2741, 2018. PMID: 29930150.
- Sampath D. Targeting deubiquitinases in CLL. Blood 130(2):100-101, 2017. PMID: 28705854.
- Sampath D. MiRly regulating metabolism. Blood 120(13):2540-1, 2012. PMID: 23019202.
- Sampath D, Garcia-Manero G. Therapy for older patients with acute myeloblastic leukemia: a problem in search of a solution. Leuk Lymphoma 53(6):1013-4, 2012. PMID: 22506546.
- Sampath D, Calin GA. Coding and Non coding: The CLL mix. Blood 115(19):3858-9, 2010. PMID: 20466868.
- Sampath D, Calin GA. miRs-Fine tuning prognosis in CLL. Blood 113(21):5035-36, 2009. PMID: 19470431.
- Sampath D, Gandhi V. Dialing resistance up a Notch. Leuk Lymphoma 50(2):158, 2009. PMID: 19235014.
Abstracts
- T-H L, Wu PJ, Mitchell S, Orwick S, Ravikrishnan J, Liu C, Mims A, Woyach J, Puduvalli V, Plunkett W, Byrd J, Lapalombella R, Sampath D. HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics. ASH Annual Meeting. San Diego, CA, 2018. e-Pub 2018.
- Mims AS, Kohlschmidt J, Eisfeld AK, Mrόzek K, Blachly JS, Orwick S, Nicolet D, Sampath D, Stone RM, Powell BL, Kolitz JE, Byrd JC, Bloomfield CD. Comparisons between TP53 Mutations and TP73 Mutations in Adult Acute Myeloid Leukemia. ASH Annual Meeting. San Diego, CA, 2018. e-Pub 2018.
- Mitchell S, Larkin KL, Greiselhuber N, T-H L, Cannon M, Orwick S, Sharma P, Asemelash Y, Zhang P, Goettl V, Beaver L, Mims AS, Puduvalli V, Blachly J, Lehman A, Harrington B, Henderson S, Breitbach, J, Willims K, Dong S, Baloglu E, Senapedis W, Kirschner K, Sampath D, Lapalombella R, Byrd JC. Selective Targeting of NAMPT by KPT-9274 in Acute Myeloid Leukemia. Blood Advances- Under Review, 2018. e-Pub 2018.
- Hing ZA, Skinner JN, Beaver LS, Lai TH, Cempre CB, Harrington BK, Sampath D, Lehman AM, Yu L, Alinari L, Byrd JC, Baiocchi RA, Lapalombella R. PRMT5 Initiates an Epigenetic Program That Promotes Progression of Chronic Lymphocytic Leukemia. Blood 2017 602:2487. ASH Annual Meeting. Atlanta, GA, 2017. e-Pub 2017.
- Rizzotto L, Bottoni A, Lai TH, Liu C, Yan PS, Ozer HG, Lapalombella R, Woyach JA, Oakes CC, Blachly JS, Sampath D. Role of Histone Deacetylase-Mediated Gene Silencing in Chronic Lymphocytic Leukemia Progression. Blood 2016 128:2705. ASH Annual Meeting. San Diego, CA, 2016. e-Pub 2016.
- Bottoni A, Lara R, Lai TH, Mantel R, Smith L, El-Gamal D, Johnson AJ, Lapalombella R, Blachly JS, Byrd JC, Woyach JA, Sampath D. Targeting BTK By a microRNA Mechanism in Chronic Lymphocytic Leukemia. Blood 2015 126:1232. ASH Annual Meeting. Orlando, FL, 2015. e-Pub 2015.
- Rizzotto L, Lai TH, Liu C, Bottoni A, Bloomfield CD, Byrd JC, Sampath D. Histone Deacetylase Inhibitors Induce microRNAs Targeting BTK in Acute Myeloid Leukemia. Blood 2015 126:1222. ASH Annual Meeting. Orlando, FL, 2015. e-Pub 2015.
- Lai TH, Zecevic A, Ewald B, Chaomei L, Rizzotto L, Sulda M, Papaioannou D, Garzon R, Plunkett W, Sampath D. HDAC Inhibition Induces microRNA-182 Which Targets Rad51 Protein and Impairs Homologous Recombination Repair to Sensitize Cells to the Double Strand Break Inducing Nucleoside Analog, Sapacitabine in AML. Blood 2015 126:3639; ASH Annual Meeting. Orlando, FL, 2015. e-Pub 2015.
- El-Gamal D, LaFollette TD, Lai H, Chenglong L, Sampath D, Lehman A, Yu L, Byrd JC, Baiocchi RA, Lapalombella R. Expression of PRMT5 in B-Cell Chronic Lymphocytic Leukemia and Its Significance in Disease Progression and Richter's Transformation. Blood 2014 124:2197. ASH Annual Meeting. San Francisco, CA, 2014. e-Pub 2014.
- Sampath D, Zecevic A, Ewald B, Hayes M, Liu C, Marcucci G, Plunkett W. Panobinostat, An Oral Pan-Histone Deacetylase (HDAC) Inhibitor Activates a Microrna Signature That Targets Rad51 To Attenuate Homologous DNA Repair and Sensitize AML Cells To Sapacitabine. ASH Annual Meeting, New Orleans, LA, 2013. e-Pub 2013.
- Sulda ML, Liu C, Keating MJ, Wierda WG, Plunkett W, Sampath D. Epigenetic silencing of miR-17 and miR-20a in chronic lymphocytic leukemia. Proceedings of the American Association for Cancer Research 53, 2012. e-Pub 2012.
- Sampath D, Liu C, Wierda WG, Plunkett W, Keating MJ. Role of histone deacetylases in silencing functionally relevant microRNAs in CLL. Proceedings of the American Association for Cancer Research 52, 2011. e-Pub 2011.
- Sampath D, Liu C, Wierda WG, Keating MJ. Epigenetic silencing of microRNA in the pathobiology of CLL. Proceedings of the American Association for Cancer research 51, 2010. e-Pub 2010.
- Zecevic A, Ewald B, Sampath D, Wierda WG, Plunkett W. Mechanism of fludarabine and oxaliplatin combined activity depends on the activity of XPF endonuclease. Proceedings of the American Association for Cancer research 51, 2010. e-Pub 2010.
- Sampath D, Liu C, Keating MJ. Epigenetic silencing of miR15a-16-1 cluster and miR29b facilitates the survival of chronic lymphocytic leukemia via maintenance of antiapoptotic survival factors. Proceedings of the American Association of Cancer Research 50, 2009. e-Pub 2009.
- Zecevic A, Ewald B, Sampath D, Wierda W, Plunkett W. Fludarabine blocks DNA repair after oxaliplatin exposure producing DNA damage and cell death. Proceedings of the American Association for Cancer research 50, 2009. e-Pub 2009.
- Ewald BJ, Sampath D, Zevevic A, Tsimberidou A, Wierda W, Plunkett W. Fludarabine and ara-C increase oxaliplatin-induced DNA damage and cytotoxicity in chronic lymphocytic leukemia. Proceedings of the American Association for Cancer Research 50, 2009. e-Pub 2009.
- Sampath D, Keating M, Plunkett W, Wierda W. Cellular response to immune gene therapy using a membrane-stable, humanized CD154 in patients with CLL. Proceedings of the American Association for Cancer Research 49, 2008. e-Pub 2008.
- Ewald B, Sampath D, Plunkett W. The DNA damage repair molecules, ATM and the Mre11-Rad50-Nbs1 complex, contribute to resistance to nucleoside analogue-induced cell death. Proceedings of the American Association for Cancer Research 49, 2008. e-Pub 2008.
- Sampath D. Chromatin modulation to target CLL. US European Alliance, 2008. e-Pub 2008.
- Sampath D, Calin G, Pudavalli V, Gopisetty G, Taccioli C, Ewald B, Keating M, Plunkett W. Specific activation of microRNA 106b targets the ubiquitin ligase ITCH to enable the p73 apoptotic responce in chronic lymphocytic leukemia. EORTC-NCI-AACR Symposium on Molecular Targets and Cancer therapeutics, 2008. e-Pub 2008.
- Sampath D, Calin G, Pudavalli V, Gopisetty G, Taccioli C, Ewald B, Keating M, Plunkett W. MicroRNA 106b targets the ubiquitin ligase ITCH to enable the p73 apoptotic responce in chronic lymphocytic leukemia. Proceedings of the American Association for Cancer Research 49, 2008. e-Pub 2008.
- Sampath D, Puduvalli V, Atadja P, Keating MJ, Plunkett W. Histone deacetylase inhibitors activate p73 to target chronic lymphocytic leukemia. International Workshop on CLL, London, United Kingdom, 2007. e-Pub 2007.
- Sampath D, Pudavalli V, Atadja P, Keating M Plunkett W. Histone deacetylase inhibitors activate p73 apoptotic responce in chronic lymphocytic. Proceedings of the American Association for Cancer Reaserch 48:967, 2007. e-Pub 2007.
- Ewald B, Sampath D, Plunkett W. Co-localization of the Mre11-Rad50-Nbs1 complex, phosphorylated ATM, and -H2AX may identify sites of nucleoside analogue-induced stalled replication forks. Proceedings of the American Association for Cancer Research 43, 2007. e-Pub 2007.
- Ewald B, Sampath D, Plunkett W. Phosphorylation of H2AX in response to a gemcitabine-induced checkpoint: Increased phosphorylation subsequent to checkpoint abrogation. Proceedings of the American Association for Cancer Research 47:491, 2006. e-Pub 2006.
- Puduvalli V, Xu J, Sampath D, Prabhu S, Lang F, Liu Y. p21/Waf1 is upregulated in ex- vivo human glioma slice cultures and delays vorinostat-induced cell cycle arrest and apoptosis in vitro. Proceedings of the American Association for Cancer Res 47, 2006. e-Pub 2006.
- Sampath D, Du M, Keating MJ, Plunkett W. Fludarabine resistance in CLL is associated with non functional p53. Proceedings of the American Association for Cancer Research 47:884, 2006. e-Pub 2006.
- Sampath D, Du M, Keating M, Plunkett W. CLL response to DNA repair inhibition: Role for p53 and XIAP. Proceedings of the American Association for Cancer Research 46:780, 2005. e-Pub 2005.
- Liu X, Sampath D, Tseng J, Matsuda A, Gesner T, Plunkett W. Abrogation of S-phase and G2 cell cycle checkpoints by small molecule inhibitors of the DNA damage kinase, Chk1. Proceedings of the American Association for Cancer Research 46:396, 2005. e-Pub 2005.
- Puduvalli V, Xu J, Sampath D. Suberoylanilide hydroxamic acid (SAHA) induces G2 arrest and apoptosis in gliomas. Proceedings of the American Association for Cancer Research 46:424, 2005. e-Pub 2005.
Book Chapters
- Lai TH, Sampath D. Assays on DNA Damage and Repair in CLL. In: Methods Mol Biol, 153-163, 2019.
- Sampath D. Role of microRNAs in leukemia. In: MicroRNA function in cancer. Springer, 97-118, 2013.
- Sampath D, Wierda W. Epigenetic regulation in CLL. In: Epigenetics of Leukemia. Springer, 2011.
- Shi Z, Sampath D, Plunkett W. Therapeutic strategies that overcome resistance to nucleoside analogs: Dysregulating checkpoint response and survival pathways by UCN-01. In: Acute Leukemia IX, 97-109, 2001.
- Gandhi V, Estey EE, Seymour JF, Sampath D, Du M, Ayers M, Keating MJ, Plunkett W. Experimental Approaches and Novel Therapies. In: Modulation of Ara-C metabolism to improve AML response. Acute Leukemias VII, 577-583, 1997.
Letters to the Editor
- Sampath D, Plunkett W. Context dependent expression of miR-106b in CLL. Blood 113: 6499, 2009.
Patient Reviews
CV information above last modified March 06, 2026